source
- Cardiovascular biotech Kardigan raises $400M in IPO, fourth 2026 $400M+ offeringKardigan, a cardiovascular drug startup, priced a $400 million initial public offering on Wednesday, adding to a recent surge in large biotech offerings. The company becomes the fourth biotech in…
- Biopharma manufacturers turn to flexible, modular facilities to meet diverse therapy demandsBiopharma development is increasingly focused on specialized and personalized treatments such as cell and gene therapies, antibody-drug conjugates and monoclonal antibodies. At the same time, the m…